Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione
Yokoyama, T., Takaki, S., Chosa, K., Sato, T., Suico, M.A., Teranishi, Y., Shuto, T., Mizuguchi, M., Kai, H.(2015) J Pharmacol Sci 129: 240-243
- PubMed: 26639444 
- DOI: https://doi.org/10.1016/j.jphs.2015.09.006
- Primary Citation of Related Structures:  
5AYT - PubMed Abstract: 
Familial amyloid polyneuropathy (FAP) is a genetic, adult-onset, neurodegenerative disorder caused by amyloid formation of transthyretin (TTR), a thyroxine-binding protein. Mutation in TTR causes a propensity of TTR tetramer to dissociate to monomer, which is the first step to amyloidosis. Thus, a drug that can stabilize the tetramer structure will have therapeutic benefit. Here, by virtual screening and biochemical assays, we identified small molecule 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione (L6) that can prevent the dissociation of TTR to monomer. X-ray crystallography reveals that L6 binds to the T4 binding pocket of TTR. These findings show that L6 is a candidate TTR stabilizer.
Organizational Affiliation: 
Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0914, Japan.